According to a UK media report, coronavirus vaccine which was developed by the University of Oxford and AstraZeneca could be cleared by health regulators by this year’s end.
The vaccine developed by the University of Oxford and AstraZeneca reached the furthest among all vaccines in clinical trials process. As per a source, NDTV reported, “We are looking at closer to six months and it is likely to be far shorter than that.”
As per a protocol developed by the Joint Committee of UK on Vaccination and Immunisation, any vaccine which is approved will be given to all those with age over 65 years, later given to younger adults who are at higher risk.
These could include those from ethnic minorities as well as ones with serious health issues. People aged over 50 will be next in line, with younger adults at the back of the queue.
100 million doses of the coronavirus vaccine have already been ordered by the government. In order to save time, the manufacturing process of doses has already begun even before they are proved successful.
According to the media report, scientists on the trial are hopeful that at the very least it will prevent 50 per cent of the infections, deemed the threshold for success.
If the vaccine is approved then the NHS of the UK will start mass vaccination immediately.
However, some of the people in the government are cautious of timelines. “Even when the vaccine is available, it does not mean within a month everybody will be vaccinated. We’re talking about six to nine months to a year after a vaccine is approved,” said Professor Nilay Shah, head of chemical engineering at Imperial College London.
The Department of Health, though, has sought to downplay the Royal Society’s findings. “This study fails to reflect the enormous amount of planning and preparation that has taken place across government to quickly roll out a safe and effective COVID-19 vaccine,” said a department spokesperson.